Inflammatory cytokines and receptors

Inflammatory cytokines and their corresponding receptors constitute a complex signaling network essential for orchestrating the body's immune and inflammatory responses (sinobiological.com). These small, soluble proteins—including interleukins, tumor necrosis factors, and interferons—bind to specific high-affinity receptors on target cells to trigger intracellular cascades like the JAK-STAT and NF-κB pathways (nih.gov, abcam.com). While vital for defense against pathogens and tissue repair, their dysregulation is a hallmark of numerous chronic conditions, including rheumatoid arthritis, inflammatory bowel disease, and cytokine storm syndromes (thermofisher.com, nih.gov). Therapeutic strategies often involve monoclonal antibodies that neutralize the cytokines themselves or block their receptors, as well as small molecules that inhibit downstream signaling (patsnap.com, nih.gov). Examples of targeted therapies include TNF inhibitors like adalimumab and IL-6 receptor antagonists like tocilizumab (royalsocietypublishing.org). However, because these molecules are fundamental to immune surveillance, their systemic inhibition carries significant risks, most notably an increased susceptibility to serious and opportunistic infections (nih.gov, sinobiological.com).

Other names

Pro-inflammatory cytokinesInflammatory mediatorsCytokine signaling systemCytokine network

Drugs targeting this class typically act by neutralizing soluble cytokines, blocking their cell-surface receptors, or inhibiting downstream intracellular signaling pathways such as the JAK-STAT or NF-κB pathways.